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Summary We have analysed the expression of interleukin-2 receptor (IL-2R) on a panel of small-cell lung
cancer (SCLC) cell lines. None of the 11 SCLC cell lines studied expressed detectable surface IL-2R a or fl
chains by indirect immunofluorescence. Reverse transcriptase-polymerase chain reaction (RT-PCR) analyses
indicated that only one out of 11 cell lines expressed detectable IL-2R ,B mRNA while two expressed a weak
positivity for IL-2R y. Five SCLC cell lines were transfected with the plasmid vector RSV.5 neo containing IL-
2 cDNA coding sequence. Stable transfectants secreted biologically active IL-2 (ranging from 25 to 100 U ml- 1
in the culture supernatant). IL-2 transfection did not produce significant modifications in the expression of
surface molecules such as IL-2R a and ,B chains, intercellular adhesion molecule-I (ICAM-1), CD44, HLA class
I and II or in IL-2R or y mRNA. More importantly, IL-2-transfected N592 and NCI H69 cell lines
completely lost their tumorigenic potential in nude mice after subcutaneous injection, whereas experimental
controls transfected with RSV.5 neo vector only, displayed an in vivo growth pattern identical to that of
untransfected cells. In addition, in the N592 model, IL-2-producing N592 inhibited the growth of wild-type
N592 injected at the same site, while injection of parental cells on the opposite side did not significantly affect
the growth of wild-type tumour cells. Histopathological analysis of the rejection process of IL-2-transfected
cells demonstrated the presence of MAC-i +, MAC-3+ macrophages and of RB68C5+ granulocytes, whereas T
cells were undetectable and NK cells were scarcely represented. In addition, a reduction of the tumour blood
vessels was observed. The possible relevance of these data for the development of vaccination strategies using
cytokine-engineered tumour cells in SCLC is discussed.
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Engineering of tumour cells with cytokine genes to enhance
their immunogenicity has been the subject of extensive
investigation in recent years (Colombo and Forni, 1994;
Schmidt-Wolf and Schmidt-Wolf, 1995). Murine models have
shown that transplantable tumour cells genetically engineered
to produce cytokines are rejected by the syngeneic
immunocompetent host. Some of these cytokines, such as
IL-2 (Gansbacher et al., 1990; Fearon et al., 1990; Cavallo et
al., 1992), IL-4, IL-7 and interferon (IFN)-gamma (Allione et
al., 1994; Colombo and Forni, 1994; Rosenthal et al., 1994)
confer resistance to the subsequent injection of wild-type
tumour cells by the induction of T-cell-mediated systemic
immunity. These studies have provided the basis for the
development of similar strategies of 'vaccination' with
genetically modified tumour cells in humans (Schmidt-Wolf
and Schmidt-Wolf, 1995).
Among the various cytokines, IL-2 is one of the most
commonly used in these studies. IL-2 mediates its stimulatory
effects on T cells via a specific high-affinity receptor that is
composed of at least three different chains involved in IL-2
binding, termed IL-2R a (CD25, p55 or TAC antigen), ,B
(p75) and y (Taniguchi and Minamy, 1993). In addition, a
functional IL-2R molecule, displaying lower affinity, com-
posed of IL-2R # and y chains, is constitutively expressed on
natural killer (NK) cells and on some T cell subsets (Voss et
al., 1992). Expression of IL-2R chains has been reported not
only on lymphoid cells but also on different human tumours,
including squamous carcinoma (Weidmann et al., 1992;
Yasumura et al., 1994), melanoma (Plaisance et al., 1993;
Rimoldi et al., 1993) and others (McMillan et al., 1995). On
these tumour cells the IL-2R was shown to be functional: IL-
2 may regulate expression of certain surface molecules such
as ICAM-1, HLA class I and class II, and CD44 (Plaisance et
al., 1993) and induce changes in the proliferative status ofthe
tumour (Yasumura et al., 1994).
Despite high sensitivity to chemotherapy and radio-
therapy, small-cell lung cancer (SCLC), which accounts for
18% of primary lung cancers, still represents, in most cases,
an incurable disease (Ihde, 1995). A clinical study suggested a
possible efficacy of exogenous IL-2 in SCLC (Clamon et al.,
1993) and therapeutic approaches based on genetic engineer-
ing of SCLC with the IL-2 gene have been proposed
(Cassileth, 1995).
Since IL-2 is active on cells derived from the neural crest
and on melanomas (Plaisance et al., 1993), which are of
neuroectodermal origin, we have first analysed whether
SCLC cells, which display neuroendocrine features, also
expressed IL-2R molecules. Information on IL-2R expression
may be of relevance to assess possible direct effects of IL-2 on
SCLC cells. In addition, we have studied the biological
properties of SCLC cell lines, stably transfected with the IL2-
gene, in vitro and in vivo in nude mice. Our results indicate
that IL-2 gene transfection in IL-2R-negative SCLC cell lines
abrogates tumorigenicity in nude mice and that IL-2-
transfected cells exert local bystander effects on the growth
of wild-type tumour cells. These findings may be related to
the activation of non-specific effector cell mechanisms or to
effects of IL-2 on the vascular endothelium.
Materials and methods
Cell lines and cultures
Small-cell lung cancer cell lines used in this study were: NCI
H146, NCI H69, NCI H446, NCI H82, NCI H128, NCI
H209 (obtained from ATCC, Rockville, MD, USA) GLC-1,
GLC-4 (kindly provided by Dr E De Vries and L De Leij,
Utrecht, Netherlands) (De Leij et al., 1985) and N592 (kindly
provided by Dr J Minna, NCI, Washington, DC, USA).
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March 1996The IST-SLl cell line was derived from a biopsy sample
obtained from a supraclavicular lymph node metastasis of a
60-year-old male patient with SCLC by culture in RPMI-
1640 medium (Hyclone, Cramlington, UK) containing 5%
fetal calf serum (FCS) and supplemented with 10-8 M
hydrocortisone, S pg ml- insulin, 10-8 M /-oestrodiol and
0.1 jg ml-' bombesin (all from Sigma, St Louis, MO, USA).
The other cells were cultured in RPMI-1640 supplemented
with 10% FCS, 2 mM glutamine and penicillin-streptomy-
cin.
Peripheral blood lymphocytes isolated from healthy
donors were activated with phytohaemagglutinin (PHA) for
72 h in culture and used as positive controls for the study of
expression of the IL-2R molecules.
Immunofluorescence analysis
Surface expression of IL-2 receptor a and chains was
analysed by indirect immunofluorescence and cytofluorimetric
analysis. The MAbs used in this study were: MAR 93, anti-
IL-2R a (kindly provided by Dr A Moretta, Genoa, Italy),
TU27, antil-IL2R # chain (Takeshita et al., 1989); T617, anti-
CD44 (kindly provided by Dr A Poggi, Genoa, Italy); W6.32,
anti-HLA class I; D1.12, anti-HLA class II (kindly provided
by Dr R Accolla, Verona, Italy) and anti-ICAMI (Bender
Medsystems, Vienna, Austria). A FITC-conjugated goat anti-
mouse immunoglobulin was used as second step reagent.
Samples were analysed with the FACScan analyser (Becton
Dickinson).
Polymerase chain reaction analysis of IL-2R expression
Total RNA was isolated by guanidium-isothiocyanate/
caesium chloride procedure. RNA (2 ,ug) was reverse
transcripted to cDNA using 0.5 pg oligo (dT),2 18 primers
(Gibco BRL, Life Technologies, Paisley, UK), 20 U RNasin
(Promega, Madison, WI, USA), 1 mM each dNTP and
200 U M-MLV reverse transcriptase (Gibco BRL) in the
buffer provided by the manufacturer in a final volume of
20 pl. The mixture was incubated at 37°C for 60 min. The
reaction was stopped at 99°C for 5 min. Two pl of the
cDNA were amplified by PCR in the presence of 0.5 pM
primers corresponding to IL-2R # and y chains (Wiedmann
et al., 1992; Plaisance et al., 1993), 2 mM each dNTPs,
10x PCR buffer (Perkin Elmer, Vaterstetten, Germany) and
2.5 U of AmpliTaq (Perkin Elmer) in a final volume of
50 p1.
The amplification was performed in a Perkin Elmer DNA
thermal cycler for 30 cycles (1 min at 95°C, 30 s at 60°C and
45 s at 72°C for IL-2R /3; 1 min at 95°C, 2 min at 60°C and
3 min at 72°C for IL-2R y) with a final extension at 72°C for
5 min.
Ten pl of amplified products were analysed on 1.5%
agarose gels and stained with ethidium bromide.
RSV.5-neo-IL-2 vector assembly and cell line transfection
The human IL-2 cDNA was amplified by RT-PCR starting
from 1 pg of total RNA of PHA-activated peripheral blood
lymphocytes. Reverse transcription and polymerase chain
reaction were carried out as described above.
The sequences ofPCR primers are the following: upstream
primer, 5' ATG CAC GAG TCG ACA CAG TAA CCT
CAA CTC CTG CC 3'; downstream primer, 5' CAA TTA
ACG GGA TCC TAG CAA ACC ATA CAT TCA AC 3'.
The RSV.5 neo/IL-2 plasmid vector was constructed by
cloning a 590 bp (SalI/BamHI) cDNA fragment containing
the complete coding region of human IL-2 into Sall and
BamHI cloning sites of RSV.5 neo (kindly provided by Dr
EO Long, NIH, NIAID, Bethesda, MD, USA) (Long et al.,
1991). N592, NCI H69, NCI H146, NCI H446 and IST-SLI
SCLC lines were transfected with 5 pg of RSV.5 neo/IL-2
plasmid using cationic liposomes (DOTAP, Boehringer
Mannheim, Mannheim, Germany) according to instructions
IL-2 gene transfection in SCLC cells
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provided by the manufacturer or by electroporation using
the Gene Pulser electroporator (Biorad, Milan, Italy).
Stable transfectants were selected with 250-500 pg ml-'
of G418 (Boehringer Mannheim) and checked for IL-2
production. To evaluate the presence of IL-2 mRNA in
transfected cell lines RT-PCR with the above primers was
carried out.
IL-2 bioassay
As indicator cell system for determination of IL-2 activity we
used the CTLL mouse cell line (kindly provided by Dr K
Smith) known to proliferate in response to human IL-2. IL-2
activity was assessed by [3H] dThd uptake by CTLL after 6 h
pulse with 0.5 pCi at the end of a 24 h period of incubation
with supernatants of transfected or parental cells. Serial
dilutions of human recombinant IL-2 (Eurocetus, Amster-
dam, The Netherlands), containing a known amount of
international units (IU) were used as standard. Serum
samples obtained from nude mice injected with IL-2-
transfected SCLC were analysed for human IL-2 by a
commercially available ELISA kit (Medgenix Diagnostics
SA, Belgium).
Nude mice studies
Pathogen-free female athymic (nu/nu, CDI) mice, 6-8 weeks
old, were obtained from Charles River (Calco, Como, Italy).
Mice were housed under sterile conditions and received
autoclaved food and water.
Animals (five mice for each group) were injected
subcutaneously with 2 x 107 wild-type or RSV.5 neo/IL-2-
transfected N592 tumour cells. To evaluate a local bystander
effect 2 x 107 wild-type and the same number of RSV.5 neo/
IL-2-transfected N592 cells were injected simultaneously at
the same site. Tumour size was measured using a caliper at
weekly intervals and was expressed as a multiple of the wider
and smaller tumour diameters. Statistical analysis was
performed by the Student's t-test.
Morphological and immunohistochemical analysis ofxenografts
Groups of three mice were euthanised 2, 4 and 7 days after
challenge. For histological evaluation, tissues were fixed in
10% neutral buffered formalin, embedded in paraffin,
sectioned at 4 gm and stained with haematoxylin and eosin
or Giemsa.
For immunohistochemistry, acetone-fixed cryostat sections
were incubated for 30 min with anti-L3T4 (CD4), anti-Lyt-2
(CD8a), anti-macrophage (M1/70.15) rat monoclonal anti-
body (MAb) (Sera-Lab, Crawley Down, Sussex, UK), anti-
MAC-1 (CDl lb/CD18), anti-MAC-3, anti-Ia MAb (Boeh-
ringer Mannheim Corp., Milan, Italy), anti-granulocyte mAb
(RB6-85C hybridoma provided by Dr RL Coffman, DNAX
Inc., Palo Alto, CA, USA), anti-endothelial cell (MEC 13.3)
(Vecchi et al., 1994) rat MAb and with anti-asialo GMI
rabbit antibodies (Wako Chemicals GmbH, Dusseldorf,
Germany). After washing, the slides were overlaid with
biotinylated rabbit anti-rat or goat anti-rabbit immunoglo-
bulins (Vector Laboratories, Burlingame, CA, USA) for
30 min. Unbound immunoglobulins were removed by
washing, and the slides were incubated with APC complex/
AP (Dako, Glostrup, Denmark).
Results
Analysis of IL-2R expression in SCLC
We have first studied the surface expression of IL-2R in
SCLC cell lines by indirect immunofluorescence and
cytofluorimetric analysis with MAbs specific for IL-2R a
and IL-2R # chains. As shown in Figure 1 and summarised
in Table I, none of the 11 SCLC lines tested expressed
detectable IL-2R a or # chains at the cell surface.IL-2 gene transfection in SCLC cells
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RT PCR analysis of IL-2R f3 and -; mRNA expression
indicated that only the NCI H82 cell line displayed a small
amount of both IL-2R fl and IL-2R r' amplification products.
while the NCI H146 cell line weakly expressed only IL-2R,
chain. All the remaining SCLC cell lines did not display
detectable transcripts for IL-2R /3 and -; chains (Figure 2 and
Table I) In addition, no changes in the IL-2R fl and p mRNA
were detected in the N592, NCI H69, NCI H 146, NCI H446
and IST-SLI cell lines after transfection with the IL-2 gene
(Figure 2).
Characterisation of stable transfvectats of SCLC cell line.s
e.xrp7essing the IL-2 genie
The SCLC cell lines N592, NCI H69, NCI H 146, NCI H446
and IST-SLI were transfected with RSV.5 neo, L-2 vector by
the use of cationic liposomes or by electroporation. Stable
transfectants, surviving to G418 selection, expressed IL-2
transcripts, which were absent in untransfected cells (Figure
2). As shown in Table II, stable transfectants secreted
biologically active IL-2, ranging from 25 to 100 IU ml ', as
evaluated by the CTLL proliferation.
The in vitro proliferative potential of IL-2-transfected cell
lines was compared with that of parental cell lines by the use
of an MTT proliferation assay. No significant changes in the
cell growth rate of N592, NCI H69, NCI H146, NCI H446
and IST-SLI were induced by IL-2 transfection (data not
shown). In addition, no modifications in the surface
expression of IL-2R a and /3, CD44, MHC-class I and
ICAM-1 molecules were observed by indirect immunofluor-
escence in IL-2-transfected cell lines (data not shown).
IL-2-tran.sfected cell line,s losye the tuniorigenic potenltial in nuldle
ni(ce and(l display local 'hystanlder' cftbct on i'ild--ti'pe tumInour
cell growth
The effect of IL-2 transfection on the in vii'o tumorigenic
potential was evaluated in a heterotopic subcutaneous model
in nude mice. As shown in Figure 3, injection of 2 x 107 wild-
26
0
0
T lymphoblasts
261
NCI H146
type N592 cells resulted in the rapid growth of a
subcutaneous tumour in three different groups of animals
injected (100% of tumour take), whereas IL-2-transfected
N592 cells displayed only a transient growth as a small
nodule and were thereafter rejected. Observation of animals
injected with IL-2 transfectants for 9 weeks did not show the
growth of any tumour mass. Injection of N592 cells
transfected with RSV.5 neo vector without IL-2 gene,
produced tumour growth with a similar kinetic to that of
parental cells with a 100% take rate. Similar results were also
observed with the IL-2-transfected NCI-H69 cell line (4/5
animals developed tumour when injected with parental cells
while none of 5 animals injected with IL-2 transfectants
produced tumour).
The N592 tumour model was also used to investigate the
possible 'bystander' effects of the IL-2 secreted by transfected
cells on the growth of simultaneously injected wild-type
tumour cells. As shown in Figure 3b and c, the subcutaneous
Table I IL-2R expression in small-cell lung cancer
IL-2Ri IL-2RJI
Cell line IF%S (MFIJ IF0% (MFI)
N592
NCI-H 128
NCI-H345
NCI-H69
NCI-H209
NCI-H 146
NCI-H446
NCI-H82
GLC-I
GLC-4
IST-SL I
T lymphoblasts
t (3)d
0 (3)
(3)
1 (3)
2 (4)
5 (4)
(3)
(3)
1 (3)
(3)
1 (3)
67 (145)
1 (3)
0 (3)
0 (3)
1 (3)
(3)
1 (4)
1 (3)
0 (3)
2 (3)
1 (3)
1 (3)
38 (12)
IL-2R/[
(PCR)
+
++1++
IL-2R;,
(PCR)
+
'Data refer to indirect immunofluorescence and represent percentage
of positive cells, whereas data in brackets refer to mean fluorescence
intensity.
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Figure 1 Cytofluorimetric analysis of IL-2R a and ft surface expression in two representative SCLC cell lines and T lymphoblasts.
Darkened area represents negative control obtained by staining cells with an isotype-matched irrelevant MAb.
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Figure 2 RT-PCR analysis of IL-2R /B(a) and y mRNA (b) expression in SCLC cell lines. In d the same cDNAs were amplified
using primers specific for ,B-actin. In c amplification with primers specific for IL-2 was performed on parental and IL-2-transfected
cell lines.
Table II IL-2 production by RSV.5 neo/IL-2 stable transfectants
Cell line IL-2 (IU ml')
N592 0 U
N592/RSV.5 neo/IL-2 25 U
NCI-H69 0 U
NCI-H69/RSV.5 neo/IL-2 50 U
NCI-H146 0 U
NCI-H146/RSV.5 neo/IL-2 25 U
NCI-H446 0 U
NCI-H446/RSV.5 neo/IL-2 100 U
IST-SLI 0 U
IST-SLI/RSV.5 neo/IL-2 25 U
Data are expressed as IL-2 IU ml-' in the supernatant of SCLC cells
subcultured for 48 h to reach a concentration of 5 x 106 ml- . The
CTLL proliferation assay was used as the detection method.
injection of a 1:1 mixture of parental and IL-2 transfected
N592 in the same site (both at 2 x 107) produced the transient
growth of a small tumour which was subsequently rejected
(only one animal out of ten had a small mass at the injection
site after 5 weeks of observation). By contrast, injection of
parental and IL-2-transfected N592 at controlateral sites
resulted in the rejection of transfected cells without
influencing the growth of parental tumour which developed
with a kinetic similar to that observed in animals injected
with parental tumour alone (Figure 3b and c).
Morphological and immunohistochemical analysis ofparental
and IL-2-transfected tumour xenografts
To gain insight into the possible host mechanisms mediating
the decreased tumorigenicity ofIL-2-producing N592 cells, we
examined in detail the morphology ofsubcutaneous tumours at
2, 4 and 7 days from nude mice injected with transfection
control or IL-2-transfected N592 cells. On day 2, N592 cells
were already in close contact with each other, and a small solid
tumour mass was evident on day 4 (Figure 4a). By the seventh
day, there was a non-encapsuled tumour with protrusions
invading the fibroadipose tissue and epidermis. Few reactive
inflammatory cells were present at the periphery ofthe tumoral
mass. These cells were immunohistochemically characterised as
RB68C5+ (granulocytes) and MAC-I', MAC-3+ Ia'
(macrophages).
After IL-2-transfected N592 cell challenge, on the other
hand, serpiginous necrotic zones were already present among
aggregates of tumour cells at day 2. On day 4 the mass was
formed of residual aggregates of severely damaged tumour
cells interspersed with large necrotic areas (Figure 4b) and on
day 7 the tumour growth area was replaced by a loose
stromal tissue. Immunohistochemical observation revealed
the presence of several granulocytes and macrophages (Figure
5a* and b*). These cells were scattered among the tumour
cells or inside and at the edges of the necrotic areas. Asialo
GM1+ cells were scarcely represented. The anti-endothelial
cell MAb showed that the necrotic areas of IL-2-transfected
N592 cell tumour were associated with a reduction of the
tumour blood vessels (Figure 5c*).
Discussion
In this study we show that SCLC cell lines do not display
detectable surface IL-2 receptors and that expression of IL-2
gene by transfection does not significantly modify their in vitro
biological characteristics. More importantly, IL-2 gene
transfection abrogated the tumorigenic potential of SCLC
cells in nude mice, possibly via activation of non-specific
effector cell mechanisms. In addition, IL-2-transfected cells
exerted a local 'bystander' effect on the growth of wild-type
tumour cells.
Previous studies showed that functional IL-2 receptor
molecules are present on some tumours and that IL-2 was
able to modify the tumour proliferative behaviour or the
expression of surface molecules relevant for the host-tumour
interaction (Plaisance et al., 1993; Yasumura et al., 1994;
McMillan et al., 1995). Our data indicate that in contrast to the
above tumours, SCLC cell lines do not express detectable
surface IL-2 receptor ox and chains, and that most ofthem also
lack expression of IL-2R ,B and y chain mRNA. The latter
finding is particularly important, since IL-2R y chain has been
shown to represent a common component (yc) of other
interleukin receptors, including IL-4R, IL-7R and IL-15R
(Sato and Miyajima, 1994).
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The finding that IL-2R is undetectable on SCLC is
consistent with the lack of in vitro biological effects of IL-2
gene expression in five SCLC lines which were stably
transfected with RSV.5 neo/IL-2. Hence, no effects on the
in vitro cell growth rate, on the surface expression of HLA,
CD44, ICAM-1, IL-2 R a and f molecules and of IL-2R ,B
and y mRNA were detected. These findings also indicate that
the loss of tumorigenicity of IL-2-tranfected tumour cells
injected into nude mice, as well as the bystander effect, is not
related to an autocrine effect of secreted IL-2 on SCLC cells,
but to the in vivo activation of host effector mechanisms.
The study of reactive cells infiltrating the IL-2-transfected
tumour during the rejection phase indicated that the effector
cells involved were mainly represented by macrophages and
granulocytes, while NK cells were scarcely represented. In
this context, IL-2 receptors have been described on
macrophages and IL-2 has been shown to act directly on
150
a)
N
.0
E
HR
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(5/5)
(0/5)
murine macrophages by enhancing their cytolytic properties
(Verstowsek et al., 1992). A similar involvement of
macrophages and neutrophils was previously reported in the
rejection phase ofmurine IL-2-engineered tumour cells by the
syngenic immunocompetent host (Cavallo et al., 1992). In
these previous studies the presence of a massive infiltrate of
neutrophils and macrophages has been attributed to the
secretion of inflammatory and chemotactic cytokines by
infiltrating tumour-specific T lymphocytes (Colombo et al.,
1992). However, in the nude mice rejection model described
herein, virtually no infiltrating T lymphocytes could be
detected during rejection. This seemed to rule out the
possibility of an involvement of residual T cell immunity in
the nude mice. Similar findings were recently reported by
Hara et al. (1995): murine melanoma cells transduced with
IL-2 were rejected in nude mice through an involvement of
macrophages without T and NK cells.
Another possibility to be considered is related to a
'capillary leak' induced by IL-2 secreted by the tumour
cells, which may alter the permeability of the vascularisation
of the growing tumour. Indeed, it has been shown that
endothelial cells express a functional IL-2R (Hicks et al.,
1991) and that IL-2 activates arachidonic acid metabolism,
influencing therefore the vascular permeability (Frazier-Scott
et al., 1988). In this context, the reduced presence of
endothelial cells in xenografted transfectants is of note
suggesting a vascular damage directly or indirectly related
to IL-2. One may speculate that these alterations may allow,
in the early phases of the rejection process, an increased
extravasation of macrophages. These cells may be activated
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Figure 3 In vivo tumorigenicity of parental N592 or IL-2-
transfected N592 cells injected subcutaneously in nude mice.
Three different experiments are shown in a, b and c. Animals were
injected with parental N592 cells (-O---), IL-2-transfected N592
cells (-O-), a mixture (1:1) of parental N592 and IL-2-
transfected cells injected at the same site (-O-) or parental cells
on one side and IL-2-transfected cells contralaterally (-A-). Data
are expressed as multiples of the wider and smaller tumour
diameters (M+s.d.). Statistically significant differences were
observed in the growth of parental cells vs IL-2-transfected cells
(P<0.001) and vs mixture of parental and transfected cells
(P<0.05 in the experiment reported in c and P<0.001 in b) 3
weeks after injection. No significant changes in the growth of
parental cells were observed when IL-2-transfected cells were
injected contralaterally (P=0.13 and P=0.6 in b and c,
respectively).
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Figure 4 Histological features of growth and rejection patterns
of N592 and IL-2-transfected N592 cells 4 days after injection
with 2 x 107 cells. (a) N592 solid tumour mass with minimal
infiltration by reactive cells. (b) Residual aggregates of several
damaged IL-2-transfected N592 cells interspersed with serpiginous
and large necrotic areas. Several reactive cells can be observed (a
and b x 630).
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Hby tumour cell products and by IL-2 to secrete inflammatory
cytokines, such as IL-1 TNFcx and IL-8, mediating further
vascular and tissue damage and neutrophil recruitment. In
this context, local secretion of TNFa could be of particular
importance in view of the cytotoxic activity of this cytokine
on tumour cells (Urban et al., 1986), the ability to augment
the cytotoxic activity and chemotactic properties of macro-
phages and neutrophils (Verstovsek et al., 1992; Ming et al.,
1987) and its effects on the vascular endothelium (Mantovani
et al., 1992). In addition, previous reports showed that
tumour cells transduced with TNFa gene lose tumorigenicity
in mice owing to the immunomodulatory effects of this
cytokine (Blankenstein et al., 1991).
IL-2 gene transfection in SCLC cells
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The finding that IL-2-transfected cells exert local but not
systemic 'bystander' effects on the growth of wild-type
tumour cells, may also be related to the fact that only low
levels of human IL-2 (<2.5 U ml-1 by ELISA) could be
achieved in the serum within the first 2-3 days after injection
of transfected cells, while undetectable levels were found after
1 week. Thus, IL-2 secreted by tumour cells may act only
locally on endothelial cells or on macrophages, while for the
induction of a systemic immunity specific T cell responses are
known to be required.
A similar rejection of IL-2-expressing tumour cells and the
existence of local 'bystander' effects on untransfected tumour
cells in nude mice have been reported in human melanoma
a*
b
c
Figure 5 Cryostat sections tested with anti-granulocytes (a) anti-macrophage (MAC-3) (b) and anti-endothelial (c) monoclonal
antibody. Granulocytes were almost absent and macrophages were very few in the tumoral growth area formed by N592 cells (a and
b), while they were more represented in the tumour growth area of IL-2-transfected cells (a* and b*). These reactive cells are
scattered among the tumour cells or inside and at the edges of the serpiginous necrotic area. A reduction of tumour blood vessels is
evident in c* (a, b, c x 630).L-2 gene transfection SCLC cels
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models (Abdel-Wahab et al.. 1994). Recent data indicate that
severe combined immunodeficiency (SCID) mice engrafted
With human fetal lung and bone marrow tissues represent a
useful model to study SCLC growth in engrafted lung tissue
(Shtivelman and Namikawa. 1995). This orthotopic model
may also offer new possibilities for analysing the anti-tumour
effects of IL-2 cell transfectants in vivo by intravenous
injection.
Regarding the possibility of inducing systemic immunity in
patients with SCLC by the use of vaccination with IL-2-
engineered tumour cells. several factors should be considered.
The recent demonstration that most SCLCs express MAGE-1
and MAGE-3 antigens (Gaugler et al.. 1994). which have
been shown to mediate HLA class-I-restricted CTL responses
in melanoma (Traversari et al.. 1992). may suggest the
possibility of inducing MAGE-l or -3-specific CTL responses
also in SCLC. However. SCLCs often display a reduced
expression of HLA-class I molecules (Doyle et al., 1985).
required for the presentation of antigemnc peptides to CTLs.
Since expression of HLA-class I antigens can be rapidly
induced on SCLC by the use of IFN-,. double transfectants
of SCLC, secreting both IL-2 and IFN--;, have been selected
in our laboratory with the aim of inducing CTL responses. In
any case. stimulation of non-specific effector cells such as
macrophages and NK cells should be achieved by the use of
SCLC transfected with IL-2 only. In this context. it should be
noted that SCLCs display sensitivity to cytolysis by NK cells
(data not shown). whose cytolyvtic activity can be greatly
potentiated by IL-2 (Ferrini et al.. 1987).
In conclusion. our present data indicate that SCLC cells
engineered to produce IL-2 are able to induce activation of
non-specific effector cell mechanisms in vivo leading to
tumour rejection. Further studies will be required to assess
the possibility of inducing a systemic immunity in humans by
engineering SCLC cells with multiple cytokines.
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